You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Andrew Han covers breaking news for GenomeWeb. He tracks companies in the sequencing and diagnostic markets.
FBB Biomed, cofounded by a diagnostics industry veteran, is attempting to develop a blood RNA test to predict COVID-19 disease severity.
The Bay Area startup is offering a no-touch method to separate cell populations for downstream analysis in genomics and synthetic biology applications.
The sequencing instrument developer is in the process of scaling and optimizing its silicon chips and plans to offer its platform by the end of next year.
The public-private partnership has published a paper on a list of indels larger than 50 bp that is already being used to develop new methods.
The firm touts a new hybridization probe design, which it says will enable small, focused panels that reduce sequencing costs and assay time.
In January a federal court unsealed a False Claims Act suit from an industry insider that alleges a Myriad subsidiary engaged in a fraudulent kickback scheme.
These hybrid capture-based methods target gene transcripts of interest, which could shrink sequencing costs for some experiments by as much as 90 percent.
The infectious disease testing firm has developed a sequencing-based coronavirus assay, which it plans to commercialize through its sister firm BioID Genomics.
Single-cell analysis, next-generation sequencing, and synthetic DNA have all been crucial to efforts to find antibodies that could neutralize SARS-CoV-2.
The diagnostics firm is conducting a 1,000-person study to find T cell profiles associated with the immune response to COVID-19 and recovery from the disease.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.
In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.